For Immediate Release: Tuesday, January 3, 2023
NARAL Pro-Choice America Applauds Food and Drug Administration’s Action on Medication Abortion
Washington, DC — Today, the U.S. Food and Drug Administration (FDA) made a significant step towards improving access to medication abortion by permanently lifting the in-person dispensing requirement for medication abortion care and establishing a new program to certify both brick-and-mortar and mail-order pharmacies to dispense mifepristone.
NARAL Pro-Choice America President Mini Timmaraju released the following statement in response:
“We applaud the FDA for following the science and taking this much welcome step to permanently lift the in-person dispensing requirement for medication abortion care and expand access through pharmacies. For more than 20 years, millions of people have used medication abortion. It is a safe, effective option. With abortion access being more restricted now than ever before, it is all the more important that we continue expanding access to care. This was a science-based decision that will empower folks to get the care they need in the way that best works for them. We look forward to continuing our work with the Biden administration to restore the right to abortion and expand abortion access for all.”
For over 50 years, NARAL Pro-Choice America has fought to protect and advance reproductive freedom at the federal and state levels—including access to abortion care, birth control, pregnancy and post-partum care, and paid family leave—for every body. NARAL is powered by its 4 million members from every state and congressional district in the country, representing the 8 in 10 Americans who support legal abortion.